Telmisartan, chemically 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid, CAS 144701-48-4, molecular formula C33H30N4O2, and molecular weight 514.62 g/mol, is an angiotensin II type 1 receptor antagonist. The pharmacopoeial substance is a white to almost white crystalline powder that is practically insoluble in water and substantially more soluble in alkaline solutions; this pH-dependent solubility is the central variable in oral and injectable formulation. The grade described as Telmisartan Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is not a single powder specification. It is a controlled active pharmaceutical ingredient that must be differentiated by particle-size distribution, residual water, residual solvents, elemental impurities, and endotoxin load according to the intended dosage form. The same chemical entity cannot be transferred directly from a tablet manufacturing stream into an injectable product without route-specific specification setting under ICH Q6A and 21 CFR 211.160.

What Pharmacopoeial Release Limits Apply to Telmisartan API?

Release testing for telmisartan API follows the telmisartan monographs of USP, Ph.Eur., and JP. The assay is determined by liquid chromatography and is expressed on the anhydrous basis; typical acceptance is 98.0% to 102.0%. Identification requires an infrared absorption spectrum concordant with the reference standard and an HPLC retention time corresponding to the standard. Organic impurities are controlled by HPLC. Individual specified impurities are generally limited to not more than 0.10%, total impurities to not more than 0.50%, and unspecified impurities to not more than 0.10%; these limits may be tightened for injectable-grade lots or for synthetic routes with known mutagenic impurities. Water content by Karl Fischer titration is normally accepted at not more than 2.0% for oral-grade API, while injectable-grade lots are often controlled below 1.0% to reduce the risk of hydrolysis during heat sterilisation and long-term storage. Residual solvents are measured by headspace gas chromatography under ICH Q3C. When dichloromethane or dimethylformamide are used in the final crystallisation, the respective limit values of 600 ppm and 880 ppm apply. Elemental impurities are determined by inductively coupled plasma mass spectrometry after closed-vessel acid digestion, with acceptance criteria derived from ICH Q3D for the intended oral or parenteral finished product.

These limits are representative release ranges rather than a single regulatory specification; the finished-product manufacturer remains responsible for establishing final acceptance criteria under 21 CFR 211.165, ICH Q6A, and the applicable regional pharmacopoeia.

Particle-Size and Solid-State Controls in Tablet, Capsule, and Granule Processing

For solid oral dosage forms, chemical purity alone does not guarantee reproducible manufacture. The low aqueous solubility of telmisartan, below 0.1 mg/mL in unbuffered water at 25 °C, makes the dissolution rate sensitive to particle surface area. Micronised telmisartan for direct-compression or dissolution-limited tablets is therefore controlled by D10, D50, and D90. A representative micronised lot may have D90 between 10 µm and 30 µm, while a granulated grade may accept D90 up to 100 µm because the wet granulation process can incorporate an alkalinising agent and densify the powder. Bulk density for milled telmisartan commonly ranges from 0.20 g/mL to 0.50 g/mL, tapped density from 0.30 g/mL to 0.70 g/mL, and the Carr index frequently exceeds 25; this indicates poor flow and requires glidant addition or granulation before high-speed tableting. Capsule filling on dosator machines shows weight variability above ±3% when the powder has a Carr index above 30, so densified granules are used rather than raw micronised powder. Solid-state identity is confirmed by X-ray powder diffraction and differential scanning calorimetry. Telmisartan exhibits multiple anhydrous and solvated forms in the patent literature; the commercial form used for oral solid dosage forms shows a melting endotherm near 260 °C. Milling must be controlled to avoid generation of amorphous material, because amorphous fractions above 20% can increase hygroscopicity and accelerate chemical degradation. Granulation with alkalinising agents such as meglumine or sodium hydroxide is performed by pre-dissolving the alkaliser in the binder solution; dry blending of free sodium hydroxide with telmisartan creates localised high-pH regions and can cause macroscopic discolouration after storage at 40 °C/75% RH. The API is incompatible with strong oxidising agents and with strongly acidic fillers that shift the microenvironment below pH 6.

In dissolution testing, the carboxylic acid group controls release. Telmisartan dissolution from unmodified powder is low in 0.1 N HCl and in pH 4.5 acetate buffer, but increases significantly in pH 7.5 phosphate buffer. Compendial dissolution testing for telmisartan tablets therefore uses a buffered high-pH aqueous medium; the typical USP apparatus configuration is 900 mL of pH 7.5 phosphate buffer at 75 rpm. The Biopharmaceutics Classification System designation of telmisartan is Class II, meaning low solubility and high permeability, so dissolution can be rate-limiting for absorption. Formulated tablets contain alkalising excipients to create a local pH above the pKa of the carboxylic acid and thereby increase dissolution rate in gastric fluid. This also explains why tablets should not be crushed and suspended in acidic beverages without pH adjustment; below pH 6.5 the drug may precipitate and the suspension can adhere to enteral feeding tubes. For immediate-release capsules, the same alkalising principle is applied, but the alkalinising agent is preferably incorporated in the granulation liquid rather than as a dry powder. The free acid can be converted to the sodium salt in situ during dissolution; the isolated sodium salt has different hygroscopicity and physical stability and requires separate assay and impurity controls.

Compared with other angiotensin II receptor blockers, telmisartan has a longer terminal elimination half-life and a slower AT1 receptor dissociation rate. The terminal half-life is approximately 24 h in adults, while valsartan has a half-life near 6 h and losartan has a parent half-life near 2 h with an active carboxylic acid metabolite. Oral bioavailability of telmisartan is 40% to 60%, plasma protein binding exceeds 99.5%, and the steady-state volume of distribution is approximately 500 L. These pharmacokinetic parameters support once-daily dosing and distinguish telmisartan from shorter-acting ARBs. In cell-based assays, telmisartan also shows partial agonism at peroxisome proliferator-activated receptor gamma at micromolar concentrations; this activity is not equivalent to thiazolidinedione activity and is not observed to the same extent with losartan or valsartan at comparable receptor-blocking concentrations. From a formulation perspective, losartan potassium is freely soluble in water, whereas telmisartan free acid is practically insoluble. Direct substitution of telmisartan into an existing losartan tablet formula is therefore not possible without changing the granulation solvent, pH modifier, and dissolution method. The lower solubility of telmisartan makes particle-size control more important and makes the API less forgiving of high-shear wet granulation errors.

Quality control of telmisartan API for oral solid dosage forms also includes particle-size method transfer. Laser diffraction measurements should be performed according to USP <429> or Ph.Eur. 2.9.31, with dry dispersion and a dispersing pressure of 0.5 bar to 3.0 bar; the selected pressure must be justified because telmisartan particles can fracture at high air pressure and generate fines. Bulk and tapped density are measured using USP <616> or Ph.Eur. 2.9.34. Powder flow is assessed by the angle of repose or shear cell; however, for micronised API, cohesive forces dominate and the angle of repose is rarely below 40°. These physical tests are not included in the pharmacopoeial monograph but are necessary for lot-to-lot control because they predict segregation and weight uniformity in downstream processing. A batch with an assay of 99% can fail tablet manufacture if the D90 shifts from 15 µm to 45 µm, because the dissolution profile may no longer meet the finished product specification in pH 7.5 buffer. Thus, the API specification includes both chemical and physical release attributes, and the dissolution specification of the finished tablet is used to confirm that the selected particle-size control remains appropriate.

When Injectable-Grade Telmisartan Demands Solubility-Enhancing Formulation

Injectable manufacture imposes additional constraints because the API is practically insoluble in water. To produce a parenteral solution, the vehicle must be alkalised with sodium hydroxide or trometamol, or a co-solvent such as propylene glycol, polyethylene glycol 300, or ethanol must be used. Published formulation studies also describe cyclodextrin complexation and lyophilised forms; however, published data for specific commercial injectable telmisartan finished products is limited. The final reconstituted solution is maintained above pH 7.5 because precipitation can occur below pH 6.5 and may plug a 0.22 µm sterilising filter. Injectable-grade API must meet bacterial endotoxin acceptance criteria established for the finished product, with the Limulus amebocyte lysate assay performed according to Ph.Eur. 2.6.14 or USP <85>. Particulate matter in the finished solution is controlled by USP <788> or Ph.Eur. 2.9.19. If a suspension or lyophilised product is manufactured, particle-size distribution is restricted, typically with D90 not more than 20 µm, to avoid needle blockage; for a true solution, particle-size control becomes secondary to clarity and filterability. Terminal sterilisation by autoclaving is permitted only after compatibility studies demonstrate acceptable impurity formation; alternatively, aseptic filtration through a 0.22 µm membrane is used. The API should not be combined with strongly acidic buffers or with amine-based additives that bring the final pH below 6.0. Light-protective filling and nitrogen sparging are used because the aqueous solution is susceptible to oxidative degradation.

During tablet manufacture, telmisartan free acid is commonly granulated with microcrystalline cellulose, mannitol, povidone, crospovidone, and an alkalinising agent. Direct compression is possible with micronised API and a dry binder, but the low bulk density and electrostatic charge of the micronised powder can cause segregation in the feed frame and sticking to tablet punches. Fluid-bed top-spray granulation is preferred; the aqueous binder solution is adjusted to alkaline pH before spraying. Inlet air temperature above 45 °C can cause the API to dissolve and re-precipitate as needle-like crystals on the granule surface, which reduces subsequent dissolution and creates visual defects. The residual moisture of granules should be below 2.0% before compression. Tablet hardness for a 200 mg core is typically 60 N to 100 N, with disintegration time less than 15 min in water at 37 °C; these values are formulation-specific and are set by design of experiments. Lubricant selection requires control of blending time. Magnesium stearate can reduce dissolution rate if blending exceeds 10 min at high shear; sodium stearyl fumarate at 0.5% to 1.0% w/w is often used to avoid this sensitivity. For capsule products, the fill material is densified by roller compaction at 8 kN to 14 kN and milled through a 0.8 mm screen. Granule blends with a Carr index below 20 provide acceptable fill weight uniformity on high-speed capsule machines; lot-to-lot variation in granule D50 above 300 µm may increase capsule weight variability and should be rejected for dosator filling.

Storage conditions for the API are controlled room temperature with protection from moisture and light. The pharmacopoeial monograph specifies storage in an airtight container. Long-term stability studies are conducted according to ICH Q1A(R2) at 25 °C/60% RH, with accelerated data at 40 °C/75% RH. Injectable-grade material is usually packaged in double low-density polyethylene bags inside aluminium-laminated sacks to limit moisture ingress. Residual solvent profiling by headspace GC is important when the synthetic route changes; if N-methylpyrrolidone is introduced, the ICH Q3C limit is 530 ppm and the solvent can persist after drying because of its high boiling point of 202 °C. Direct-compression grade should be re-screened if storage humidity exceeds 60% RH, and the processing suite should be maintained at 21 °C to 25 °C with relative humidity not more than 50%. Micronised powder is electrostatically active; earthing of sieving and blending equipment, and the use of dehumidified compressed air, reduce caking, sampling error, and cross-contamination risk. The chemical entity is identical across dosage forms, but the release specification, particle engineering, and microbial controls are route-specific. A lot acceptable for tablet compression is not automatically acceptable for sterile injectable manufacture unless the endotoxin, particulate, and residual solvent controls are also met.